Combination Therapy using an Innovative Bioadhesive Polymeric Transmucosal Delive
Combination Therapy using an Innovative Bioadhesive Polymeric Transmucosal Delive
批准号:
8449582
负责人:
GITA SHANKAR
金额:
$22.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2014-03-31
关键词:
AcyclovirAntiviral AgentsBuffersCaviaCell Culture TechniquesCharacteristicsClinical TrialsCombined Modality TherapyContraceptive AgentsDevelopmentDevelopment PlansDoseDrug FormulationsDrug KineticsElementsEnvironmentEpithelial CellsEpitheliumExcretory functionExhibitsFemaleFundingGelHIVHIV-1Human Herpesvirus 2HypersensitivityInfectionInternationalLactobacillusLegal patentLifeMetabolismMethodsModelingMusOryctolagus cuniculusPharmaceutical PreparationsPhasePlacebosPolymersPredispositionPropertyRelative (related person)ResearchResearch PersonnelRiskSIVSafetySexually Transmitted DiseasesSimplexvirusSurfaceSyringesTenofovirTestingTherapeuticTimeTissuesToxic effectToxicologyVaginaVirus DiseasesWomanWorkabsorptionbasebiocompatible polymercondomsgenital herpeshydroxyethylcellulosein vivo Modelinnovationirritationmicrobicidemouse modelmucoidnonhuman primatenovelnovel strategiespandemic diseasepre-clinicalpreclinical safetyprototyperesearch studyresidencescaffoldscale uptopical antiviraltransmission processvaginal microbicide
中文摘要
描述(由申请人提供):一种局部阴道组合杀微生物剂将有助于遏制艾滋病毒和单纯疱疹病毒大流行的传播,使妇女能够保护自己免受艾滋病毒/单纯疱疹病毒感染,并可能防止其他性传播疾病,特别是当避孕套被认为是不可接受的或无法获得的时候。杀微生物剂必须是无刺激性的,并且不会增加感染。由于缺乏药效,可能是由于在阴道表面的停留时间有限,几种杀菌剂未能通过临床试验。长时间的表面接触是必不可少的。生物粘合剂被归类为生物相容聚合物,可以延长杀菌剂在阴道内的停留时间,从而最大限度地减少频繁给药的需要,其聚合物支架也可以帮助溶解药物。开发一种单独用作杀菌剂的无毒生物粘合剂,并将其与抗病毒化合物结合,既可以延长抗病毒药物的停留时间,又可以增加进一步的保护性能。我们建议使用我们获得专利的创新双元素SR-2P生物黏附聚合物开发一种组合杀菌剂,在阴道表面提供两种治疗药物,同时保护这种脆弱的组织,并创造一个有助于阻止人类免疫缺陷病毒(HIV)-1感染的低pH环境。我们将单独测试这种新配方的固有杀菌性能,并将其与替诺福韦和阿昔洛韦一起配方,以展示一种安全有效的控制HIV-1感染的原则证明产品,结合使用,将优于目前的凝胶配方。SRI研究人员进行的初步研究表明,含有替诺福韦的SR-2P不会引起任何阴道刺激。对于
在R21期,我们将首先优化使用和不使用替诺福韦和阿昔洛韦的SR-2P,使其具有强大的生物粘附性和pH缓冲性能,并将药物释放到阴道上皮。在批量试生产中,我们将生产足够的药物产品,以便在随后的安全性和有效性研究中进行测试。将在阴道刺激模型中研究SR-2P单独和与药物联合使用的安全性,以证明该制剂无毒和无刺激性。为了在R33阶段进一步开发SR-2P,我们将在体内的几个模型中测试SR-2P在使用和不使用替诺福韦和阿昔洛韦的情况下的安全性和有效性。同时,我们将对这两种形式进行加速稳定性研究。使用标准的临床前安全性和毒理学方法,我们将进行阴道药代动力学/吸收;分布、代谢、排泄和毒性研究;以及临床前安全性实验,以证明SR-2P是无刺激性的,不会引起组织过敏。我们预计这些研究将证明SR-2P是一种安全有效的杀微生物剂,可以帮助减少艾滋病毒和单纯疱疹病毒感染的进一步传播。
英文摘要
DESCRIPTION (provided by applicant): A topical vaginal combination microbicide will help contain the spread of the HIV and HSV pandemic by allowing women to protect themselves against HIV/HSV infection and possibly from other sexually transmitted diseases, especially when condoms are considered unacceptable or are unavailable. The microbicide must be nonirritating and not enhance infection. Several microbicides have failed clinical trials because of lack of efficacy, possibly from limited residence time on the vaginal surface. Prolonged surface contact is essential. Bioadhesives, which are classified as biocompatible polymers, may lengthen vaginal microbicide residence time, thus minimizing the need for frequent dosing, and their polymer scaffold can also help solubilize drugs. Developing a nontoxic bioadhesive that acts as a microbicide on its own and combining it with antiviral compounds will both lengthen residence time for the antiviral medication and add further protective properties. We propose to develop a combination microbicide using our patented, innovative, dual-element SR-2P bioadhesive polymer to deliver two therapeutics to the vaginal surface while simultaneously protecting this delicate tissue and creating a low-pH environment that aids in blocking human immunodeficiency virus (HIV)-1 infection. We will test this novel formulation both alone, for its inherent microbicidal properties; and formulate it with tenofovir and acyclovir, to demonstrate a safe and effective proof-of-principle product for the control of HIV-1 infections that, in combination, will be superior to current gel formulations. Preliminary studies performed by SRI researchers indicate that the SR-2P with tenofovir does not elicit any vaginal irritation. For the
R21 phase, we will first optimize SR-2P with and without tenofovir and acyclovir to have strong bioadhesive and pH buffering properties, and to release drugs to the vaginal epithelium. In pilot batch manufacturing, we will produce sufficient drug product to test in subsequent safety and efficacy studies. Safety of SR-2P alone and in combination with the drugs will be investigated in a vaginal irritation model to demonstrate that the formulation is nontoxic and nonirritating. To develop SR-2P further in the R33 phase, we will test microbicide safety and efficacy of SR-2P with and without tenofovir and acyclovir in several models in vivo. Concurrently, we will perform accelerated stability studies on both forms. Using standard preclinical safety and toxicology methods, we will conduct vaginal pharmacokinetics/absorption; distribution, metabolism, excretion, and toxicity studies; and preclinical safety experiments to demonstrate that SR-2P is nonirritating and causes no tissue hypersensitivity. We anticipate that these studies will demonstrate that SR-2P is a safe and efficacious microbicide that can help reduce the further spread of HIV and HSV infections.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeutic.
SR-2P 阴道杀菌剂凝胶作为预防性药物和暴露后治疗药物联合使用时,可提供针对单纯疱疹病毒 2 型的保护。
DOI:
10.1128/aac.00690-15
发表时间:
2015
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Fields,ScottA, Bhatia,Gaurav, Fong,JulieM, Liu,Mingtao, Shankar,GitaN]
通讯作者:
Shankar,GitaN
Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel.
创新型双聚合物 (SR-2P) 生物粘附阴道凝胶的配方开发和评估。
DOI:
10.1208/s12249-014-0124-9
发表时间:
2014
期刊:
AAPS PharmSciTech
影响因子:
3.3
作者:
[Podaralla,Satheesh, Alt,Carsten, Shankar,GitaN]
通讯作者:
Shankar,GitaN
DEVELOP A QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) PLAN FOR ACTIVITIES CONDUCTED UNDER TASK AREA D.
-
批准号:9545135
-
项目类别:
-
资助金额:$2.73万
-
财政年份:2017
-
负责人:GITA SHANKAR
-
依托单位:
Combination Therapy using an Innovative Bioadhesive Polymeric Transmucosal Delive
-
批准号:8812524
-
项目类别:
-
资助金额:$51.38万
-
财政年份:2014
-
负责人:GITA SHANKAR
-
依托单位:
Oral Radiation Nuclear Decorporation Agents
-
批准号:9357476
-
项目类别:
-
资助金额:$4.06万
-
财政年份:2010
-
负责人:GITA SHANKAR
-
依托单位:
DEVELOPMENT OF IMPROVED DTPA FOR RADIONUCLIDE CHELATION
-
批准号:7543562
-
项目类别:
-
资助金额:$165.3万
-
财政年份:2005
-
负责人:GITA SHANKAR
-
依托单位:--
NASAL ANTHRAX VACCINE DELIVERY FORMULATIONS
-
批准号:6759853
-
项目类别:
-
资助金额:$9.68万
-
财政年份:2004
-
负责人:GITA SHANKAR
-
依托单位:
海外基金